Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July5, 2017, Synergy Pharmaceuticals Inc. (the “Company”) filed an amendment (the “Amendment”) to its second amended and restated certificate of incorporation, as amended, to increase the number of authorized shares of common stock from 350,000,000 to 400,000,000. The Amendment was approved by the Company’s stockholders at the Company’s 2017 annual meeting held on June27, 2017. A copy of the Amendment filed with the Secretary of State of the State of Delaware is filed as Exhibit3.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

3.1 Amendment to the Second Amended and Restated Certificate of Incorporation, as amended, filed with the Delaware Secretary of State on July5, 2017.

SYNERGY PHARMACEUTICALS, INC. Exhibit
EX-3.1 2 a17-17004_1ex3d1.htm EX-3.1 Exhibit 3.1   CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SYNERGY PHARMACEUTICALS INC. (a Delaware Corporation)   PURSUANT TO SECTIONS 242 OF THE DELAWARE GENERAL CORPORATION LAW   SYNERGY PHARMACEUTICALS INC.,…
To view the full exhibit click here

About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.